Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Confluence Life Sciences, a St. Louis-based developer of kinase inhibitors for cancer and other diseases, has been acquired by Aclaris Therapeutics for $10 million in cash and stock. Dermatology-focused Aclaris says the deal adds a preclinical inhibitor of the MK2 pathway, implicated in arthritis and other autoimmune diseases, as well as earlier-stage molecules targeting other inflammation pathways. Confluence was founded by former Pfizer scientists after layoffs at the big pharma firm’s St. Louis site in 2009.
This article has been sent to the following recipient: